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Despite the effectiveness of endocrine therapies to treat estrogen receptor-positive (ER+) 
breast tumours, two thirds of patients will eventually relapse due to de novo or acquired 
resistance to these agents. Cancer Stem-like Cells (CSCs), a rare cell population within the 
tumour, accumulate after anti-estrogen treatments and are likely to contribute to their failure. 
Here we studied the role of p21-activated kinase 4 (PAK4) as a promising target to overcome 
endocrine resistance and disease progression in ER+ breast cancers. PAK4 predicts for 
resistance to tamoxifen and poor prognosis in 2 independent cohorts of ER+ tumours. We 
observed that PAK4 strongly correlates with CSC activity in metastatic patient-derived 
samples irrespective of breast cancer subtype. However, PAK4-driven mammosphere-
forming CSC activity increases alongside progression only in ER+ metastatic samples. PAK4 
activity increases in ER+ models during acquired resistance to endocrine therapies. Targeting 
PAK4 with either CRT PAKi, a small molecule inhibitor of PAK4, or with specific siRNAs 
abrogates CSC activity/self-renewal in clinical samples and endocrine-resistant cells. 
Together, our findings establish that PAK4 regulates stemness during disease progression and 
that its inhibition reverses endocrine resistance in ER+ breast cancers. 
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Abstract 
Despite the effectiveness of endocrine therapies to treat estrogen receptor-positive (ER+) 
breast tumours, two thirds of patients will eventually relapse due to de novo or acquired 
resistance to these agents. Cancer Stem-like Cells (CSCs), a rare cell population within the 
tumour, accumulate after anti-estrogen treatments and are likely to contribute to their failure. 
Here we studied the role of p21-activated kinase 4 (PAK4) as a promising target to overcome 
endocrine resistance and disease progression in ER+ breast cancers. PAK4 predicts for 
resistance to tamoxifen and poor prognosis in 2 independent cohorts of ER+ tumours. We 
observed that PAK4 strongly correlates with CSC activity in metastatic patient-derived 
samples irrespective of breast cancer subtype. However, PAK4-driven mammosphere-
forming CSC activity increases alongside progression only in ER+ metastatic samples. PAK4 
activity increases in ER+ models during acquired resistance to endocrine therapies. Targeting 
PAK4 with either CRT PAKi, a small molecule inhibitor of PAK4, or with specific siRNAs 
abrogates CSC activity/self-renewal in clinical samples and endocrine-resistant cells. 
Together, our findings establish that PAK4 regulates stemness during disease progression and 
that its inhibition reverses endocrine resistance in ER+ breast cancers. 
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Highlights 
• PAK4 predicts for failure of endocrine therapies and poor prognosis  
• PAK4 drives stemness and progression in ER+ metastatic breast cancer 
• Targeting PAK4 abrogates breast CSC activity and restores sensitivity to endocrine 
treatments 
• Targeting PAK4 will improve outcome of ER+ breast cancer patients 
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1. Introduction 
Endocrine resistance is a major problem for the treatment of Estrogen Receptor (ER)-positive 
breast tumours. Despite their undoubted benefit in clinical practice, anti-estrogen therapies 
fail for at least two thirds of ER+ breast cancer patients due to de novo or acquired resistance, 
which eventually lead to metastatic relapse [1]. Several studies have reported that Cancer 
Stem-like Cells (CSCs) are enriched following endocrine therapies [2-4] . This rare 
population of cancer cells with stem-like features and tumour-initiating ability is enriched by 
radio-, chemo- and endocrine therapies, and likely to be responsible for their failure and 
subsequent disease progression [4-6]. Different molecular mechanisms account for the 
development of endocrine resistance, which mainly revolve around ER function. In fact, ER 
expression is absent or low in breast CSCs [7]. In addition to the loss of ER, other 
mechanisms are the acquisition of gain-of-function mutations in ESR1 [8-11] or expression of 
truncated ER variants [12] as disease progresses to an advanced state. Moreover, aberrant 
expression of cell cycle regulators that counteract the cytostatic effect of anti-estrogens or the 
deregulation of receptor tyrosine kinase signalling (e.g. overexpression of epidermal growth 
factor family, EGFR and HER2; or insulin-like growth factor family) lead to activation of 
downstream pathways that can also modulate sensitivity to endocrine therapies [13-15]. 
These pathways have been successfully targeted by CDK4/6 and PI3K/mTOR inhibitors, 
leading to some benefit in ER+ patients [16-18]. 
p-21 activated kinases (PAKs) recently emerged as a potential druggable target to overcome 
endocrine resistance [19]. This conserved family of serine/threonine kinases, originally 
described as downstream effectors of small Rho GTPases, Rac and Cdc42, is crucial for 
cytoskeletal dynamics, survival, proliferation, metabolism and invasion. In mammals, six 
members have been identified and classified into two groups based on sequence and structure 
similarities: Group I, PAK1-3; and Group II, PAK4-6. PAK function is upregulated in many 
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human cancers (including melanoma, hepatocellular carcinoma, pancreatic, ovarian, prostate 
and breast cancer) [20-25], and copy number aberrations have frequently been described in 
the chromosomal regions containing PAK1 and PAK4 genes [20, 21, 24, 26-28]. Data 
supporting a role in breast cancer include oncogenic transformation of immortalised mouse 
mammary epithelial cells by PAK4 overexpression and PAK4 RNAi reversing the malignant 
phenotype of MDAMB231 breast cancer cells [29, 30]. Moreover, 3 independent studies on 
the expression of PAK4 in breast clinical specimens at different disease stages showed that 
high protein levels correlate with larger tumour size, lymph node involvement and invasive 
disease [31-33]. Furthermore, PAK4 expression associates with poor clinical outcome in 
tamoxifen-treated patients and was demonstrated to positively regulating ER transcriptional 
activity in an endocrine resistant breast cancer cell line [34].  
Here we show PAK4 predicts resistance to tamoxifen and poor prognosis in 2 cohorts of ER+ 
breast cancer tumours. Using patient-derived breast tumour cells, we demonstrate that 
blockade of PAK4 signalling using a small molecule inhibitor reduces CSC activity and 
overcomes endocrine resistance. In metastatic patients, we show PAK4 expression is 
associated with endocrine resistant cancer progression. Our results indicate that PAK4 is 
essential for maintaining CSC features in patient-derived ER+ metastatic breast cancers and 
in acquired resistance to endocrine therapies. We conclude that the use of anti-PAK4 
therapies will help tackle resistance in ER+ breast cancer patients. 
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2. Materials and methods 
2.1. Identification and Characterisation of CRT PAKi 
Several compounds which inhibit PAK4 were identified out of a high-throughput screening 
on ∼80,000 small molecules from the Cancer Research UK’s Commercial Partnerships Team 
(formerly known as Cancer Research Technology, CRT) compound collection. Exploration 
of the structural-activity relationship was carried out around novel ATP competitive 
chemotypes, with compounds being routinely tested against both PAK4 and PAK1 (Supp. 
Figure 1A). “Hit compounds” were selected to progress to a cellular pharmacodynamic 
biomarker assay, which measured the inhibition of phosphorylation of a direct substrate of 
PAK4; and also, to examine toxicity by looking at drug metabolism and pharmacokinetics 
(DMPK) in vitro. Among all, CRT PAKi showed greater potency, low microsomal intrinsic 
clearance and reduced colony formation in a dose-dependent manner in established cell lines 
of different origin (Table I & II). 1 µM of CRT compound was profiled against the kinase 
assay panel of 456 targets (LeadHunter Panels, DiscoverX), showing a promising off-target 
profile.  In vivo pharmacokinetic studies showed that its bioavailability was 49 %, and that 
high levels of the compound were detected in the muscle up to 7 h post-administration (Supp. 
Figure 1B) [23]. CRT PAKi was prepared in-house at Cancer Research UK Therapeutic 
Discovery Laboratories (purity >99% by LCMS and HNMR) and provided by Cancer 
Research UK’s Commercial Partnerships Team (London, UK). 
 
2.2. Cell lines and reagents 
Endocrine-resistant MCF-7 cell lines were kindly provided by Dr Julia M. Gee (University of 
Cardiff, Wales) [13], [35]. Parental MCF-7 cells were cultured in phenol-red DMEM/F12 
media containing 10 % foetal bovine serum and 2 mM L-glutamine. Tamoxifen-resistant 
(TAMR) and Fulvestrant-resistant (FULVR) MCF-7 cells were routinely cultured in phenol-
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red DMEM/F12 media supplemented with 5% charcoal-stripped serum and 2 mM L-
glutamine in the presence of either 0.1 µM 4-OH-Tamoxifen or 0.1 µM Fulvestrant, 
respectively. 4-OH-Tamoxifen (Sigma-Aldrich, Cat. No.#H7904, purity ≥ 98% by HPLC) 
and Fulvestrant (TOCRIS Bioscience, Cat. No.#1047, purity ≥99% by HPLC) were 
purchased. 
 
2.3. Metastatic patient-derived samples 
Metastatic samples from breast cancer patients were collected at both The Christie NHS 
Foundation Trust and The University Hospital of South Manchester NHS Foundation Trust 
through the Manchester Cancer Research Centre Biobank (Manchester, UK). Patients were 
informed and consented according to local National Research Ethics Service guidelines 
(Ethical Approval Study No.: 05/Q1402/25 and 12/ROCL/01). Sample processing to isolate 
breast cancer cells from metastatic fluids (pleural effusions or ascites) was carried out as 
described elsewhere [36]. 
 
2.4. Cell proliferation 
Cell proliferation was carried out using the Sulforhodamine B (SRB) assay [37]. Briefly, 
1,500 cells were seeded per well in 96-well plates. Plates were incubated at 37 °C in a 
humidified incubator with 5 % CO2 until cell attached to the substrate. Then a plate was set 
aside for a no-growth control (day 0) and treatment was added to the rest. Cells were treated 
with either 0.5 µM CRT PAKi, 1 µM tamoxifen, 100 nM fulvestrant, combination of 
therapies or vehicle control. Treatment-containing media was refreshed every three days. At 
different time points, cells were fixed by adding 25 µl of cold 50 % trichloroacetic acid 
(TCA) to each well and incubating the plates at 4 °C for at least 1 h. Plates were washed 5 
times with water and left to air dry. Then cells were stained with 100 µl of 0.057 % SRB in 
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1% acetic acid solution at room temperature for 30 min. Then unbound dye was washed away 
by rinsing quickly with 1% acetic acid for several times and left air dry. SRB was dissolved 
by adding 200 µl of 10 mM Tris pH 10.5 to each well for 5 minutes at room temperature and 
absorbance at 510 nm was measure using a Versa Max microplate reader (Molecular 
Devices).  
 
2.5. Colony formation assay 
The assay was performed as described elsewere [38]. Briefly, 500 cells were seeded per well 
in 6-well plates in the presence of either 0.5 µM CRT PAKi, 1 µM tamoxifen, 100 nM 
fulvestrant, combination of therapies, vehicle control or left untreated (control). After 10-18 
days, media was removed and cells washed once with PBS following by fixation with 
acetone/methanol (1:1) for 30 seconds. Fixative was removed and plates were allowed to air 
dry. Then plates were rinsed with distilled water and stained with Giemsa dye for 2-3 minutes 
or until colour of colonies is strong. Rinse with distilled water twice and air dry. Colonies 
were counted using a GelCount colony counter (Oxford Optronix).  
 
2.6. Quantitative Real-Time PCR 
mRNA expression was detected using and quantitative RT-PCR. Total RNA was extracted at 
different conditions and qRT-PCR reactions were performed as described in [2]. Applied 
Biosystems Taqman Gene Expression Assays used: PAK1, #Hs000945621_m1; PAK4, 
#Hs00110061_m1; GAPDH, #Hs99999905_m1; and ACTB, #Hs99999903_m1. 
Expression levels were calculated using the ∆∆Ct quantification method using GAPDH and 
ACTB as housekeeping genes. 
 
2.7. Western blot 
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Cells lysates were prepared by resuspending cells in cell lysis buffer (25 mM HEPES, 50 mM 
NaCl, 10 % glycerol, 1 % Triton-X-100, 5 mM EDTA) containing proteases and 
phosphatases inhibitors (Roche MiniProtease Inhibitor cocktail; 1 µM PMSF; 30 mM sodium 
pyrophosphate; 50 mM sodium fluoride; 1 µM sodium orthovanadate). Then cells were 
incubated on rotation for 1h at 4°C, and subsequently protein lysates were obtained by 
centrifugation at 12,000 g at 4°C for 10 min. Protein concentration was determined using 
BCA Protein Assay Kit (Pierce). Samples were prepared under reducing conditions, 
subsequently loaded in pre-cast 10% gels (BioRad, #456-1033) and run at 200 V. Then 
proteins were transferred to a 0.2 µm Nitrocellulose membrane (BioRad, #170-4159) at 25 V 
for 15 min 1.3 A using the Transblot Turbo Transfer System (BioRad). Membranes were 
blocked in 5% bovine serum albumin (BSA)/ PBS-0.001% Tween 20 (PBS-T) for 1h at room 
temperature, followed by incubation with primary antibody diluted in 5% BSA/PBS-T at 4°C 
overnight. Primary antibodies used: anti-PAK1 (Cell Signaling, #2602), anti-PAK4 (Cell 
Signaling, #3242), β-actin (Sigma, #A2228). After 3 washes with PBS-T, HRP-conjugated 
secondary antibodies (Dako) were incubated for 1h at RT. Blots were developed using 
Luminata Classico (Millipore, Merck) and hyperfilm (Amersham GE Healthcare). 
 
2.8. Mammosphere-forming assay 
Cancer stem cell activity was assessed by the mammosphere-forming assay following the 
protocol described in [39]. When indicated, cells were directly treated in mammosphere 
culture with either 0.01-1 µM CRT PAKi (or control vehicle, DMSO); 1 µM 4-OH-
Tamoxifen or 100 nM Fulvestrant (or control vehicle, ethanol). 
 
2.9. PAK4 silencing 
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PAK4 expression was silenced in MCF-7 TAMR cells using siRNA technology. TAMR cells 
were transfected with either 10 nM control siRNA (Dharmacon, D-001810-01), siPAK4 #1 
(Ambion, S20135) or siPAK4 #2 (Quiagen, SI049900000). Transfection was performed 
using DharmaFECT (Dharmacon) following the manufacturer’s instructions. Then 
transfected cells were harvested 48h post-transfection and PAK4 downregulation was 
confirmed by Western blot and quantitative RT-PCR.  
 
2.10. Gene expression meta-analyses of ER+ primary breast tumours  
The gene expression data on 669 ER+ tamoxifen-treated tumours (GSE6532, GSE9195, 
GSE17705, and GSE12093) and 343 ER+ untreated tumours (GSE2034 and GSE7390) was 
integrated from published Affymetrix microarray datasets with correction for batch effects as 
described previously [2]. Comprehensive survival analysis was conducted using the 
survivALL R package to examine Cox proportional hazards for all possible points-of-
separation (low-high cut-off points) [40]. 
 
2.11. Statistics 
Statistical significance was determined using GraphPad Prims software. Normal distribution 
of data was assessed using D’Agostino-Pearson, Shapiro-Wilk and Kolmogorov-Smirnov 
normality tests. Normal Parametric tests including one-way ANOVA with Tukey’s multiple 
comparisons test or two-tailed unpaired Student’s t-test were performed. When normality 
assumption was not possible, non-parametric Kruskal-Wallis with Dunn’s multiple 
comparisons test or non-parametric Mann-Whitney test were performed. Data are always 
expressed as mean ± SEM of at least 3 independent experiments.  A p-value ≤0.05 was 
considered statistically significant.  
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3. Results  
3.1. PAK4 predicts for tamoxifen resistance and poor prognosis in ER+ breast cancer 
Overexpression of PAK1 and 4 in ER+ breast tumours that are refractory to endocrine 
therapy have previously been linked to tamoxifen resistance and poor prognosis [23, 34, 41, 
42]. However, PAK4 is the only family member that associates with clinical outcome data 
using relapse-free survival as endpoint [34]. Then we assessed whether PAK1/4 expression 
would predict for patient outcome to tamoxifen treatment using overall survival data from 2 
independent ER+ breast cancer patient cohorts. We carried out meta-analyses using four 
published Affymetrix gene expression datasets. Initially, a comprehensive survival analysis 
was performed on 669 pre-treated tumours of ER+ breast cancer patients, who subsequently 
received tamoxifen as adjuvant therapy. After ranking gene expression data by PAK4 (low to 
high expression), all possible points-of-separation and their significance are shown in the 
survivALL plots (Supp. Figure 2A). The heatmap indicates PAK4 expression is independent 
of PAK1, ESR1, PGR, ERBB2 or the marker of proliferation AURKA (Figure 1A & B). At 
most significant cut-point, the subsequent Kaplan-Meier survival analysis revealed that high 
levels of PAK4 were significantly correlated with metastatic relapse (Figure 1A, bottom 
panel). In contrast, only very high or very low levels of PAK1 were associated with 
metastasis (Supp. Figure 2C & E). However, elevated levels of both PAKs were associated 
with poor clinical outcome showing reduced overall survival in an independent cohort of 
untreated ER+ breast cancer patients (n=343; Figure 1B, Supp. Figure 2B, D, F). Thus, PAK4 
could be used as a prognostic tool to identify ER+ breast cancer patients with high risk of 
developing endocrine resistance and therefore benefit from the use of anti-PAK4 therapies in 
the adjuvant setting. 
 
3.2. PAK4 expression correlates with CSC activity in metastatic breast cancer patients 
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PAK1/4 expression was measured in 18 patient-derived metastatic samples, including all 
clinically defined breast cancer subtypes (Table III, Figure 2A & 2B). We found that their 
expression was unrelated to subtype and that PAK4 was more frequently detected and more 
highly expressed that PAK1. In breast cancer cell lines, PAK4 but not PAK1 mRNA 
expression was significantly associated with luminal subtype (Supp. Figure 3A, B). In 
patient-derived samples, there was a highly significant correlation of PAK4 mRNA 
expression and cancer stem cell (CSC) activity measured using the mammosphere-forming 
assay (Figure 2C, Pearson correlation coefficient = 0.810; p-value < 0.00005; Supp. Figure 
3B, Pearson correlation coefficient = 0.104; p-value = 0.682). Next, we tested the effect of 
increasing concentrations of a PAK1/4-specific inhibitor (CRT PAKi) on the mammosphere-
forming efficiency. This compound has an encouraging off-target profile indicating high 
selectivity for PAK1/4 (Figure 2D). In 9 metastatic patient-derived samples PAK1/4 
inhibition reduced cancer stem cell activity in a dose-dependent manner (Figure 2E). Further 
sub-group analysis showed this effect was due to its activity in ER+ metastatic breast cancer 
samples, with PAK1/4 inhibition impairing breast CSC activity up to 60 % (Figure 2F); 
whereas the CSC activity of triple negative samples (n=2) remained unaffected in the 
presence of the CRT compound (Supp. Figure 3D, E). These data suggest that PAK4 
expression is important in the maintenance of the CSC pool in metastatic ER+ breast cancer. 
 
3.3. PAK1/4 expression is related to cancer progression 
Next, we examined sequential metastatic samples of 2 ER+ breast cancer patients. The 
patients’ clinical treatment history is summarized in Figure 3A & B. Our analyses showed 
that both PAK1/4 protein levels and CSC activity increased alongside with disease 
progression. We detected increased expression of both PAK family members in samples from 
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patient BB3RC44 (∼2 or 1.6-fold for PAK1/4, respectively, Figure 2A), whereas a striking 
increase of PAK1 levels was observed in patient BB3RC81 (∼65-fold, Figure 2B).  
These results show that an increase in PAK1/4 expression is correlated with disease 
progression in ER+ breast cancers, establishing their involvement in the failure of endocrine 
therapies. 
 
3.4. PAK4 downregulation restores endocrine sensitivity in resistant cells 
These patient data suggest either PAK1 or -4 or both have a role in endocrine resistance. 
To test our hypothesis, we used in vitro ER+ MCF-7 cell lines of acquired resistance after 
long-term exposure to either tamoxifen (TAMR) or fulvestrant (FULVR), respectively [13, 
35]. Initially, we assessed the expression of PAK1/4 in parental, TAMR and FULVR cells. 
Both PAK1 and PAK4 were overexpressed in resistant cells compared to parental cells 
(Figure 4A). However, short-term treatment with tamoxifen or fulvestrant in MCF-7 cells did 
not induce a significant upregulation of PAK1/4 gene expression (data not shown).  To 
further confirm the role of PAK1/4 in endocrine resistance and stemness, we evaluated CSC 
activity for endocrine resistant cells in the presence of CRT PAKi. PAK1/4 chemical 
inhibition abrogated CSC self-renewal (>95 % in TAMR and 80 % in FULVR, respectively; 
Figure 4B) but not primary mammosphere formation (Supp. Figure 4A). Similarly, PAK4 
silencing in TAMR and FULVR cells not only impaired breast CSC activity (Figure 4C & 
Supp. Figure 4B-D), but also restored their sensitivity to tamoxifen and fulvestrant, 
respectively (Figure 4D & Supp. Figure 4E). These findings indicate that breast CSC activity 
in endocrine resistant cells depends on PAK4, which can be targeted to overcome endocrine 
resistance. We hypothesized that PAK4 inhibition in combination with endocrine therapies 
will benefit ER+ breast cancer patients. To test this, initially we assessed the effect of CRT 
PAKi on proliferation and colony formation in endocrine resistant cells (Figure 5). We found 
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that the compound specifically reduced proliferation and colony formation in TAMR and 
FULVR (Figure 5A&B), but it had no impact on growth in parental cells (Figure 5A). 
However, CRT PAKi interfered with cell attachment of parental cells as colony formation 
was significantly impaired (Figure 5B). This phenotype may be due to the pivotal role of 
PAK signalling in adhesion, as main effector of Rac/Cdc42 during filopodia and lamellipodia 
formation [43, 44].  (Figure 5C&D). Moreover, the presence of CRT PAKi with either 
tamoxifen or fulvestrant had a significant cooperative effect reducing proliferation and 
colony formation of endocrine resistant cells even further (Figure 5A, C, D).   
To confirm our findings, we treated 4 ER+ patient-derived breast cancer metastatic samples 
with either fulvestrant or CRT PAKi as single agents or in combination. CRT PAKi on its 
own did not have a significant effect on MFE but its combination with the standard of care 
fulvestrant had a synergistic effect reducing CSC activity more than half. When patient-
derived samples were separated into responders versus non-responders, we identified that 
only ER+ breast cancer patients with high levels of PAK4 benefit from the combination of 
therapies (Figure 4E and Supp. Figure 4F), suggesting PAK4 expression is a predictive 
biomarker of response. These results confirm the importance of targeting PAK4 to potentiate 
endocrine therapy and overcome resistance. 
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4. Discussion 
Despite the remarkable impact on survival caused by the introduction of endocrine therapies 
for the treatment of ER+ breast cancers, late recurrences occur in some patients due to the 
development of resistance to these single agents. Several authors have shown that breast CSC 
activity and frequency are enhanced upon endocrine therapies such as tamoxifen and 
fulvestrant, suggesting that this drug-resistant population accounts for the eventual metastatic 
relapse [2, 3]. Here we report for first time that PAK4 signalling is essential for maintaining 
CSC features in ER+ metastatic breast cancers. Also, PAK4 can be used as a predictive 
biomarker of response to endocrine therapies, and furthermore, its inhibition reverses 
endocrine-driven resistance in ER+ breast cancer patients.  
The relationship between PAK4 and stemness has previously been described in pancreatic 
cancer cell lines [45, 46]. In this study, pancreatic CSCs express high levels of PAK4 and its 
silencing reduced not only sphere formation, but also stem cell-related markers [46]. In 
agreement with these findings, we found that PAK4 significantly correlated with 
mammosphere-forming ability, and treatment with CRT PAKi reduced breast CSC activity in 
a dose-dependent manner in metastatic samples of all subtypes. Using RNA-seq data from 10 
breast cancer Patient-Derived Xenografts (PDXs), we observed that PAK4 expression 
correlated with DLL1, NOTCH1-4, PTCH and GLI1 (data not shown). These genes are 
involved in NOTCH or Hedgehog signalling, both developmental pathways that regulate 
CSC homeostasis and self-renewal [47]. 
Most importantly, the effect of PAK4 inhibition on CSCs is restricted to ER+ metastatic 
samples, as the presence of CRT PAKi did not alter CSC activity of ER- subtype. In fact, 
PAK4 expression significantly correlated with stem cell-related genes such as SOX2, 
POU5F1 or ALDH1A3 only in metastatic ER+ PDXs (data not shown). PAK4 is often 
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amplified in basal-like cancers, which give rise to TNBC [26]; and silencing PAK4 or using 
inhibitors that induce protein destabilisation reduce proliferation and in vivo tumorigenesis in 
TNBC, but not in ER+ or HER2+ cell lines [29, 48]. This discrepancy in the role of PAK4 
between breast cancer subtypes might be either associated with its additional kinase-
independent functions [33, 49], which are compromised upon reducing protein levels and 
therefore could drive tumorigenesis in TNBC; or, instead, with off-target activity of these 
inhibitors, e.g. affecting enzymes involved in NAD metabolism [50]. Mechanistically, 
differences among subtypes can be related to the presence of ER, as a positive feedback loop 
has been described where ER promotes PAK4 expression and, in turn, PAK4 regulates its 
transcriptional activity in endocrine resistant cells [34]. Further investigation is needed to 
fully understand the specific resistance mechanism in each breast cancer subtype. 
In most adult tissues, PAK4 expression is low. However, its overexpression has not only been 
associated with oncogenic transformation [29, 30], but also with disease stage in breast 
clinical specimens [31-33]. We found that PAK1/4-driven CSC activity increased as the 
disease progressed in sequential metastatic samples taken from 2 ER+ breast cancer patients. 
However, PAK4 expression only increased during progression in patient BB3RC44, who 
received several lines of endocrine therapy after metastatic relapse, suggesting a resistant 
phenotype. Whereas patient BB3RC81 was treated with just chemotherapy after recurrence 
and progression seems to rely on a PAK1-dependent mechanism.  
Then we confirmed overexpression of PAK4 in endocrine resistant MCF7 cells. Importantly, 
CRT PAKi abrogated almost completely CSC self-renewal and silencing of PAK4 not only 
reduced mammosphere formation, proliferation and colony formation, but also restored the 
effect of tamoxifen and fulvestrant in endocrine resistant cells. However, experiments with 
cell line-derived and/or patient-derived xenografts would be essential to demonstrate 
endocrine treatment response in vivo.  Restoration of sensitivity has already been reported 
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using GNE-2861, a group II PAK inhibitor, in tamoxifen-resistant MCF7/LCC2 cells [34]. 
Furthermore, blocking PAK4 in combination with standard of care fulvestrant reduced CSC 
activity even further in ER+ breast cancer metastatic samples with high levels of PAK4. 
Therefore, PAK4 not only has prognostic value as confirmed using overall survival data as 
clinical end point; but it is also a predictive biomarker of response to endocrine therapies. 
Thus ER+ breast cancer patients with high levels of PAK4 could be identified and benefit for 
using PAK-targeting therapeutics. In recent years, considerable efforts have been made to 
develop PAK inhibitors. PF-3758309, which targets group I and II PAKs, was the first PAK 
inhibitor to enters clinical trials for advanced solid tumours. Although it blocks growth of a 
variety of tumour cell lines in vitro and in vivo, it failed in phase I due to adverse 
pharmacological properties and side effects [51]. Since then, many attempts have been made 
to develop novel small molecules inhibitors with good oral bioavailability [52]. KPT-9274 is 
currently in phase I clinical trials for solid tumours and lymphomas. The inhibitory 
mechanism and off-target effects of this destabilising agent still remain to be elucidated. 
Although it has been reported to be promising for controlling tumour growth in TNBC, ER+ 
and HER2+ cell lines are unresponsive [48]. Therefore, other strategies must be considered to 
target ER+ disease. Here we showed that blocking only kinase-dependent functions of PAK4 
using CRT PAKi is sufficient to overcome endocrine resistance. 
 
In conclusion, we report for first time that PAK4 is a promising target to reduce CSC activity 
in ER+ metastatic breast cancers and furthermore its expression can be used as a prognostic 
and preventive tool for patient stratification to identify those who will benefit from 
complementary anti-PAK4 therapies. 
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Figure 1. PAK4 predicts for tamoxifen resistance and poor prognosis. Expression of 
PAK1, ESR1, PGR, HER2 and AURKA genes in 2 independent cohorts of ER+ breast cancer 
patients treated with tamoxifen (A) or untreated (B) is shown in the heatmaps ranked based 
on PAK4 expression. Colours are log2 mean-centered values; red indicates high, whereas 
green indicates low expression levels. All significant cut-points (p< 0.05) are shown in grey. 
Kaplan-Meier analyses using the most significant cut-point (white dashed line) demonstrates 
that elevated expression of PAK4 is significantly associated with increased distant metastasis 
(A) and decreased overall survival (B). 
 
Figure 2. PAK4 expression correlates with stemness in metastatic breast cancer. 
Expression of PAK1/4 was detected at RNA (A) or protein (B) level in 18 metastatic breast 
cancer patient-derived samples (including all breast cancer subtypes). β-actin was used as 
loading control. (C) CSC activity of freshly processed metastatic samples assessed by the 
mammosphere-forming assay was correlated to relative PAK4 mRNA expression. (D) The 
off-target liability and on-target specificity of CRT PAKi is summarised in a TREEspot 
kinase dendrogram. 1 µM of CRT compound was screened and profiled against a kinase 
assay panel of 456 targets, which covers more than 80 % of human protein kinome 
(LeadHunter Panels, DiscoverX), using a quantitative site-directed competition binding assay 
[53]. In this human kinome phylogenetic tree, each kinase screened is marked with a circle. 
Red circles identify kinases found to bind, where larger circles show higher affinity binding; 
whereas small green circles indicate not significant binding. TK, non-receptor tyrosine 
kinases; TKL, tyrosine kinase-like kinases; STE, homologous to yeast STE7, STE11 and 
STE20 kinases; CK1, casein kinase 1 family; AGC, containing Protein Kinase A, G and C 
families; CAMK, calcium/calmodulin dependent kinases; CMGC, consists of cyclin-
dependent kinases (CDK), MAPK, glycogen-synthase-3 (GSK3) and CDC-like kinases 
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(CLK); OTHER, other kinases. Image generated using TREEspot Software Tool and 
reprinted with permission from KINOMEscan, a division of DiscoveRx Corporation, 
DISCOVERX CORPORATION 2010.  
(E) Overall effect of PAK1/4 inhibition using a range of concentrations of CRT PAKi on 
CSC activity was evaluated in metastatic patient-derived samples. (F) Detail of CRT 
compound effect in ER+ metastatic samples. MFE, mammosphere-forming efficiency. 
Stats, p-values: *≤0.05; **<0.01; ****<0.0001. 
 
Figure 3. PAK1/4 and CSC activity increases during cancer progression. Examination of 
sequential samples of 2 ER+ metastatic patients, BB3RC44 (A) and BB3RC81 (B). The 
clinical treatment history of each patient is summarized in the top panels. Colours: light blue, 
pink or green indicate hormonal, chemo- or bone-directed therapy, respectively. Orange 
arrows pointed when the samples were taken. PAK1/4 protein levels and CSC activity 
measured as mammosphere-forming efficiency (MFE) are shown in bottom panels.  
Densitometric values of the ratio PAK to β-actin are indicated below the blots. 
 
Figure 4. PAK4 downregulation restores anti-estrogen sensitivity in resistant cells. (A) 
PAK1/4 expression was detected in endocrine resistant MCF-7 cells by Western Blot. Right 
panel shows densitometric analyses referred to β-actin expression as control of even protein 
loading. (B) Second generation mammospheres were plated to assess for mammosphere self-
renewal (MSR) of cells treated in the first generation with 0.5 µM CRT PAKi or vehicle 
(DMSO) in resistant cells. (C) Effects of PAK4 silencing on CSC activity in TAMR cells. 
Two different siRNAs were used against PAK4 (siPAK#1, siPAK#2). Then CSC activity of 
siRNA-transfected TAMR cells was evaluated using the mammosphere-forming assay. The 
inset shows PAK1/4 mRNA expression in siRNA-transfected cells. In the right upper panels, 
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PAK4 downregulation at protein level was observed by Western Blot. In the right lower 
panel, densitometric analyses referred to β-actin expression as control of even protein loading 
are shown. (D) PAK4-silenced TAMR cells were cultured with either 1 µM tamoxifen or 
vehicle control (ethanol) during the mammosphere-forming assay. Mammosphere-forming 
efficiency (MFE) is shown. (E) Combination of PAK4 inhibition and anti-estrogen therapies 
in ER+ metastatic breast cancer. Mammosphere-forming efficiency of patient-derived 
samples treated with either 0.5 µM CRT PAKi, 100 nM fulvestrant or both therapies was 
assessed.  
Stats, p-values: * ≤0.05; **<0.01; ***<0.001; ****<0.0001. 
 
 Figure 5. PAK1/4 inhibition specifically reverses endocrine resistance. (A) Cell 
proliferation using the SRB assay was assessed in ER+ MCF7 parental and endocrine 
resistant cells. Cells were treated with either vehicle control, 0.5 µM CRT PAKi, 1 µM 
tamoxifen, 100 nM fulvestrant or the combination for 15 days. Cells were fixed at different 
time points during the assay. Fold change was calculated by normalisation of Absorbance at 
510 nm to no-growth control (day 0).  (B) Colony formation assay was carried out in parental 
and endocrine resistant MCF7 cells. Cells were plated in the presence of 0.5 µM CRT PAKi., 
vehicle or left untreated (control). Additionally, the effect of CRT PAKi in combination with 
1 µM tamoxifen (C) or 100 nM fulvestrant (D) was tested in TAMR and FULVR, 
respectively. Upper panels show a representative example of colonies formed for each cell 
line and treatment. Lower panels show the percentage of colony formation normalised to 
vehicle. Data correspond to mean values (± SEM) from three independent experiments. Stats, 
p-values: * ≤0.05; **<0.01; ***<0.001; ****<0.0001. 
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Table I. In vitro cellular pharmacodynamics, drug metabolism and pharmacokinetics of 
CRT PAKi 
 
 CRT PAKi 
PAK4 pIC50 at 20 µM ATP 7.5 
PAK1 pIC50 at 16 µM ATP 8.0 
PD Biomarker pIC50  6.9 
Microsomal Cl Int (ml/min/g liver) 1.91 
 
 
 
pIC50 values in the presence of ATP, the ability of inhibiting phosphorylation of a direct 
substrate of PAK4 and the microsomal intrinsic clearance are shown. 
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Table II. Effect of CRT PAKi on proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anchorage independent growth was assessed in cancer cell lines of different origin and pIC50 
values for the compound were calculated. 
  CRT PAKi 
Phenotypic pIC50 (anchorage 
independent growth)
 
pancreatic 6.2 
breast 6.3 
ovarian  6.3 
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Table III. Characteristics of late metastatic breast cancer patient-derived samples used in the study 
1
 
                                                          
1
 ILC, invasive lobular carcinoma; IDC, intraductal carcinoma; ER; estrogen receptor; PR, progesterone receptor; HER2, Human 
epidermal growth factor receptor 2; Neg, negative; EOX, Epirubicin/Oxaliplatin/Capecitabine; FEC, 
5Fluorouracil/Epirubicin/Cyclophosphamide; 5FU, 5Fluorouracil; CMF, Cyclophosphamide/Methotrexate/5Fluorouracil; ECF, 
Epirubicin/Cisplatin/5Fluorouracil; AC, cyclophosphamide/doxorubicin; NK, not known. 
Sample Histology Grade 
Receptor status 
Chemo 
Hormone 
Therapy 
Targeted 
Therapy ER PR HER2 
BB3RC44 ILC 3 + + Neg EOX 
Capecitabine 
Paclitaxel 
Letrozole 
Tamoxifen 
Exemestane 
Fulvestrant 
Herceptin 
Lapatinib 
BB3RC45 IDC 3 + + + FEC 
Paclitaxel 
Capecitabine 
Vinorelbine 
Epirubicin 
Tamoxifen 
Anastrazole 
Zometa/pomidronate 
Herceptin 
 
BB3RC52 IDC 3 + + Neg Epirubicin 
Vinorelbine/5FU 
CMF 
Docetaxel 
Tamoxifen 
Fulvestrant 
Herceptin 
BB3RC44A ILC 3 + + Neg EOX 
Capecitabine 
Paclitaxel 
Letrozole 
Tamoxifen 
Exemestane 
Fulvestrant 
Herceptin 
Lapatinib 
BB3RC44B ILC 3 + + Neg EOX 
Capecitabine 
Paclitaxel 
Letrozole 
Tamoxifen 
Exemestane 
Fulvestrant 
Herceptin 
Lapatinib 
BB3RC68 IDC 2 + NK Neg FEC-60 
Capecitabine 
Taxol 
Tamoxifen 
Fulvestrant 
 
BB3RC70 ILC 2 + + Neg ECF Tamoxifen 
Letrozole 
Anastrozole 
 
BB3RC71 IDC 3 + + + FEC 
Capecitabine 
Vinorelbine 
Taxotere 
Epirubicin 
Tamoxifen 
Anastrozole 
Fulvestrant 
Exemestane 
Herceptin 
Lapatinib 
BB3RC77 ILC ? + + Neg Paclitaxel 
Capecitabine  
Eribulin 
Letrozole 
Exemestane 
Fulvestrant 
Ibandronate 
BB3RC78 IDC 2 + Neg Neg Epirubicin 
 
Letrozole 
Exemestane 
Denosumab 
Everolimus 
BB3RC79 IDC 3 Neg Neg Neg FEC/Docetaxel 
Gemcitabine/Carboplatin 
  
BB3RC81 IDC 2 + + Neg Paclitaxel 
Capecitabine 
NK  
BB3RC81A IDC 2 + + Neg Paclitaxel 
Capecitabine 
NK  
BB3RC84 NK NK Neg Neg Neg AC 
Docetaxel 
Ixabepilone/Capecitabine 
/Bevacizumab 
Cisplatin/Gemcitabine 
Tamoxifen  
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Figure 1. PAK4 predicts for Tamoxifen resistance and poor prognosis
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Figure 2. PAK4 expression correlates with stemness in metastatic 
PDS 
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Figure 3. PAKs expression increases during cancer progression
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Figure 4. PAK4 downregulation restores anti-estrogen sensitivity in 
resistant cells
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Figure 5. PAK1/4 inhibition specifically reverses endocrine resistance
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• PAK4 predicts for failure of endocrine therapies and poor prognosis  
• PAK4 drives stemness and progression in ER+ metastatic breast cancer 
• Targeting PAK4 abrogates breast CSC activity and restores sensitivity to endocrine 
treatments 
• Targeting PAK4 will improve outcome of ER+ breast cancer patients 
 
